medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2021-33-38-41medalphabet-2324Research ArticleРЕВМАТОЛОГИЯRHEUMATOLOGYДиагностическое значение моноспецифических антител к DFS70 при системных аутоиммунных ревматических заболеванияхDiagnostic value of monospecifc DFS70 antibodies in systemic utoimmune rheumatic diseaseshttps://orcid.org/0000-0003-4074-5907АлександроваЕ. Н.AleksandrovaE. N.

Александрова Елена Николаевна, д.м.н., зав. лабораторией клинической иммунологии

Москва

Aleksandrova Elena N., DM Sci (habil.), head of Laboratory of Clinical Immunology

Moscow

e.aleksandrova@mknc.ruhttps://orcid.org/0000-0002-2738-2956НовиковА. А.NovikovA. A.

Новиков Александр Александрович, д.б.н., в.н.с. лаборатории клинической иммунологии

Москва

Novikov Alexander A., Dr Bio Sci (habil.),, leading researcher, Laboratory of Clinical Immunology

Moscow

a.novikov@mknc.ruhttps://orcid.org/0000-0002-6471-9415КлюквинаН. Г.KlyukvinaN. G.

Клюквина Наталия Геннадьевна, д.м.н., в.н.с. отдела ревматологии

Москва

Klyukvina Natalia G., DM Sci (habil.), leading researcher, Dept of Rheumatology

Moscow

n.klyukvina@mknc.ruhttps://orcid.org/0000-0002-1425-8622ВасильевВ. И.VasilievV. I.

Васильев Владимир Иванович, д.м.н., проф., врач-ревматолог

Москва

Vasiliev Vladimir I., DM Sci (habil.), professor, rheumatologist

Moscow

rheumacardiolog@yandex.ruhttps://orcid.org/0000-0001-7958-5926ЛукинаГ. В.LukinaG. V.

Лукина Галина Викторовна, д.м.н., проф., зав. отделом ревматологии

Москва

Lukina Galina V., DM Sci (habil.), professor, head of Dept of Rheumatology

Moscow

g.lukina@mknc.ruГБУЗ «Московский клинический научно-практический центр имени А. С. Логинова Департамента здравоохранения города Москвы»РоссияA. S. Loginov Moscow Clinical Scientific CenterRussian FederationООО «Ревмоцентр»РоссияRevmocentre Co.Russian Federation202113122021033Ревматология в общей врачебной практике (2)3841Copyright © Александрова Е.Н., Новиков А.А., Клюквина Н.Г., Васильев В.И., Лукина Г.В., 20212021Александрова Е.Н., Новиков А.А., Клюквина Н.Г., Васильев В.И., Лукина Г.В.Aleksandrova E.N., Novikov A.A., Klyukvina N.G., Vasiliev V.I., Lukina G.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2324

Обнаружение в сыворотке крови моноспецифических антител, индуцирующих плотное мелкокрапчатое свечение при взаимодействии с DFS70 / LEDGF / р75 – ядерным антигеном, негативно ассоциируется с развитием системных аутоиммунных ревматических заболеваний (САРЗ) и повышает диагностическую специфичность скринингового исследования антинуклеарных антител (АНА) методом непрямой реакции иммунофлюоресценции на HEp-2 – клетках (НРИФ-HЕp-2), однако результаты оценки клинического значения антител к DFS70 варьируют в зависимости от используемых тест-систем и подбора групп больных. Цель работы: изучить частоту обнаружения моноспецифических антител к DFS70 в сыворотках крови у здоровых лиц и больных САРЗ. Исследованы сыворотки 74 здоровых доноров и 59 больных САРЗ: 27 – с системной красной волчанкой (СКВ), 15 – с синдромом Шегрена (СШ), 17 – с ревматоидным артритом (РА). Классические антинуклеарные антитела (АНА) и антитела к DFS70 определяли с помощью НРИФ при использовании в качестве субстрата смеси стандартных и генно-инженерных DFS70-KO HEp-2 – клеток, не экспрессирующих DFS70 / LEDGF / р75. Серопозитивными по антинуклеарному фактору (АНФ) были 14,9% здоровых доноров и 83,1% больных САРЗ (96,3% – СКВ, 100,0% – СШ, 47,1% – РА). Классические АНА с гомогенным, крапчатым, ядрышковым, цитоплазматическим, смешанным типами свечения и отсутствием антител к DFS70 обнаружены у всех АНФ-позитивных больных САРЗ и у 8,1% здоровых доноров. Моноспецифические антитела к DFS70 без классических АНА выявлены у 6,8% здоровых лиц и отсутствовали при САРЗ. Среди АНФ-позитивных здоровых доноров частота изолированного обнаружения антител к DFS70 составляла 45,5%. Выявление моноспецифических антител к DFS70 в сыворотке крови может рассматриваться в качестве потенциального предиктивного маркера для исключения диагноза САРЗ у АНФ-позитивных пациентов с отсутствием или нечетко выраженными клиническими признаками данных заболеваний.

The detection in serum of monospecifc antibodies that induce a dense fne-speckled fluorescence when interacting with the DFS70 / LEDGF / p75 nuclear antigen is negatively associated with the development of systemic autoimmune rheumatic diseases (SARD) and increases the diagnostic specifcity of the screening study of antinuclear antibodies (ANA) using indirect immunofluorescence on HEp-2 cells (IIF-HEp-2). The results of assessing the clinical signifcance of anti-DFS70 antibodies vary depending on the test systems and the selection of patient groups. The aim of this work is to study the frequency of detection of monospecifc anti-DFS70 antibodies in blood serum in healthy individuals and patients with SARD. Sera of 74 healthy donors and 59 patients with SARD were studied (27 – systemic lupus erythematosus – SLE, 15 – Sjogren's syndrome – SjS, 17 – rheumatoid arthritis – RA). Classical antinuclear antibodies (ANA) and anti-DFS70 antibodies were determined by IIF using a mixture of standard and genetically engineered DFS70-KO HEp-2 cells that do not express DFS70 / LEDGF / p75 as a substrate. 14.9% of healthy donors and 83.1% of SARD patients (96.3% – SLE, 100.0% – SS, 47.1% – RA) were seropositive for antinuclear factor (ANF). Classical ANA with homogeneous, speckled, nucleolar, cytoplasmic, mixed types of fluorescence and the absence of anti-DFS70 antibodies were found in all ANF-positive patients with SARD and in 8.1% of healthy donors. Monospecifc anti-DFS70 antibodies without classical ANA were detected in 6.8% of healthy individuals and were absent in SARS. Among ANF-positive healthy donors, the frequency of isolated detection of anti-DFS70 antibodies was 45.5%. The detection of monospecifc anti-DFS70 antibodies can be considered as a potential predictive marker for excluding the diagnosis of SARD in ANF-positive patients with no or unclear clinical signs of these diseases.

антинуклеарные антителаантитела к DFS70системная красная волчанкаревматоидный артритсиндром Шегренанепрямая реакция иммунофлюоресценции на HEp-2 ELITE/DFS70-KO – клеткахantinuclear antibodiesanti-DFS70 antibodiessystemic lupus erythematosusrheumatoid arthritisSjogren's syndromeindirect immunofluorescence assay on HEp-2 ELITE/DFS70-KO cellsReferencesАлександрова Е.Н., Новиков А.А., Насонов Е.Л. Лабораторная диагностика ревматических заболеваний. В кн.: Насонов Е.Л., ред. Российские клинические рекомендации. Ревматология. М.: ГЭОТАР-Медиа; 2019: 302–20.Aleksandrova E.N., Novikov A.A., Nasonov E.L. Laboratory diagnosis of rheumatic diseases. In Nasonov E.L., ed. Russian Clinical Guidelines. Rheumatology. [Rossiyskie Klinicheskie Rekomendatsii. Revmatologiya.]. Moscow: GEOTAR-Media; 2017: 300–18 (in Russian).Agmon-Levin N., Damoiseaux J., Kallenberg C., Sack U., Witte T., Herold M. et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014; 73 (1): 17–23.Agmon-Levin N., Damoiseaux J., Kallenberg C., Sack U., Witte T., Herold M. et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014; 73 (1): 17–23.Chan E.K., Damoiseaux J., Carballo O.G., Conrad K., de Melo Cruvinel W., Francescantonio P.L. et al. Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014–2015. Front Immunol. 2015; 6: 412.Chan E.K., Damoiseaux J., Carballo O.G., Conrad K., de Melo Cruvinel W., Francescantonio P.L. et al. Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014–2015. Front Immunol. 2015; 6: 412.Mahler M., Meroni P. L., Bossuyt X., Fritzler M. J. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res. 2014; 2014: 315179.Mahler M., Meroni P. L., Bossuyt X., Fritzler M. J. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res. 2014; 2014: 315179.Meroni P.L., Biggioggero M., Pierangeli S.S., Sheldon J., Zegers I., Borghi M.O. Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases. Nat Rev Rheumatol. 2014; 10 (1): 35–43.Meroni P.L., Biggioggero M., Pierangeli S.S., Sheldon J., Zegers I., Borghi M.O. Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases. Nat Rev Rheumatol. 2014; 10 (1): 35–43.Tozzoli R., Bonaguri C., Melegari A., Antico A., Bassetti D., Bizzaro N. Current state of diagnostic technologies in the autoimmunology laboratory. Clin Chem Lab Med. 2013; 51: 129–38.Tozzoli R., Bonaguri C., Melegari A., Antico A., Bassetti D., Bizzaro N. Current state of diagnostic technologies in the autoimmunology laboratory. Clin Chem Lab Med. 2013; 51: 129–38.Damoiseaux J., Andrade L. E.C., Carballo O. G., Conrad K., Francescantonio P.L.C., Fritzler M.J., et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis. 2019; 78 (7): 879–889. DOI: 10.1136/annrheumdis-2018–214436.Damoiseaux J., Andrade L. E.C., Carballo O. G., Conrad K., Francescantonio P.L.C., Fritzler M.J., et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis. 2019; 78 (7): 879–889. DOI: 10.1136/annrheumdis-2018–214436.Abeles A.M., Abeles M. The clinical utility of a positive antinuclear antibody test result. Am J Med. 2013; 126 (4): 342–8.Abeles A.M., Abeles M. The clinical utility of a positive antinuclear antibody test result. Am J Med. 2013; 126 (4): 342–8.Fritzler M.J. Choosing wisely: Review and commentary on anti-nuclear antibody (ANA) testing. Autoimmun Rev. 2016; 15 (3): 272–80.Fritzler M.J. Choosing wisely: Review and commentary on anti-nuclear antibody (ANA) testing. Autoimmun Rev. 2016; 15 (3): 272–80.Mahler M., Fritzler M.J. The clinical signifcance of the dense fne speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases. Clin Dev Immunol. 2012; 2012: 494356.Mahler M., Fritzler M.J. The clinical signifcance of the dense fne speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases. Clin Dev Immunol. 2012; 2012: 494356.Conrad K., Röber N., Andrade L.E., Mahler M. The clinical relevance of anti-DFS70 autoantibodies. Clin Rev Allergy Immunol. 2017; 52 (2): 202–216.Conrad K., Röber N., Andrade L.E., Mahler M. The clinical relevance of anti-DFS70 autoantibodies. Clin Rev Allergy Immunol. 2017; 52 (2): 202–216.Ochs R.L., Mahler M., Basu A., Rios-Colon L., Sanchez T.W., Andrade L.E. et al. The signifcance of autoantibodies to DFS70/LEDGFp75 in health and disease: integrating basic science with clinical understanding. Clin Exp Med. 2016; 16 (3): 273–93.Ochs R.L., Mahler M., Basu A., Rios-Colon L., Sanchez T.W., Andrade L.E. et al. The signifcance of autoantibodies to DFS70/LEDGFp75 in health and disease: integrating basic science with clinical understanding. Clin Exp Med. 2016; 16 (3): 273–93.Mahler M., Andrade L.E., Casiano C.A., Malyavantham K., Fritzler M.J. Anti-DFS70 antibodies: an update on our current understanding and their clinical usefulness. Expert Rev Clin Immunol. 2019; 15 (3): 241–50.Mahler M., Andrade L.E., Casiano C.A., Malyavantham K., Fritzler M.J. Anti-DFS70 antibodies: an update on our current understanding and their clinical usefulness. Expert Rev Clin Immunol. 2019; 15 (3): 241–50.Malyavantham K., Suresh L. Analysis of DFS70 pattern and impact on ANA screening using a novel HEp-2 ELITE/DFS70 knockout substrate. Auto Immun Highlights. 2017; 8 (1): 3.Malyavantham K., Suresh L. Analysis of DFS70 pattern and impact on ANA screening using a novel HEp-2 ELITE/DFS70 knockout substrate. Auto Immun Highlights. 2017; 8 (1): 3.Petri M., Orbai A.M., Alarcón G.S., Gordon C., Merrill J.T., Fortin P.R. et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classifcation criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64 (8): 2677–86.Petri M., Orbai A.M., Alarcón G.S., Gordon C., Merrill J.T., Fortin P.R. et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classifcation criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64 (8): 2677–86.Aletaha D. Neogi T. Silman A. et al. 2010 rheumatoid arthritis classifcation criteria. Arthritis Rheum. 2010; 62: 2569–2581.Aletaha D. Neogi T. Silman A. et al. 2010 rheumatoid arthritis classifcation criteria. Arthritis Rheum. 2010; 62: 2569–2581.Васильев В.И. Болезнь (синдром) Шегрена. В кн.: Насонов Е.Л., ред. Российские клинические рекомендации. Ревматология. М.: ГЭОТАР-Медиа; 2019: 230–41.Vasiliev V.I. Sjögren’s Syndrome. In Nasonov E.L., ed. Russian Clinical Guidelines. Rheumatology. [Rossiyskie Klinicheskie Rekomendatsii. Revmatologiya.]. Moscow: GEOTAR-Media; 2019: 230–41 (in Russian).Shiboski S.C., Shiboski C.H., Criswell L.A., Baer A., Challacombe S., Lanfranchi H. et al. American College of Rheumatology classifcation criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012; 64 (4): 475–87.Shiboski S.C., Shiboski C.H., Criswell L.A., Baer A., Challacombe S., Lanfranchi H. et al. American College of Rheumatology classifcation criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012; 64 (4): 475–87.Shiboski C.H., Shiboski S.C., Seror R., Criswell L.A., Labetoulle M., Lietman T.M. et al. 2016 American College of Rheumatology/European League Against Rheumatism classifcation criteria for primary Sjögren's Syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017; 69 (1): 35–45.Shiboski C.H., Shiboski S.C., Seror R., Criswell L.A., Labetoulle M., Lietman T.M. et al. 2016 American College of Rheumatology/European League Against Rheumatism classifcation criteria for primary Sjögren's Syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017; 69 (1): 35–45.Mariz H. A., Sato E. I., Barbosa S. H., Rodrigues S. H., Dellavance A., Andrade L.E. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating anti-nuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum. 2011; 63: 191–200.Mariz H. A., Sato E. I., Barbosa S. H., Rodrigues S. H., Dellavance A., Andrade L.E. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating anti-nuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum. 2011; 63: 191–200.Carter J.B., Carter S., Saschenbrecker S., Goeckeritz B.E. Recognition and relevance of anti-DFS70 autoantibodies in routine antinuclear autoantibodies testing at a community hospital. Front Med (Lausanne). 2018; 5: 88eb 11.Carter J.B., Carter S., Saschenbrecker S., Goeckeritz B.E. Recognition and relevance of anti-DFS70 autoantibodies in routine antinuclear autoantibodies testing at a community hospital. Front Med (Lausanne). 2018; 5: 88eb 11.Infantino M., Meacci F., Grossi V., Manfredi M., Li Gobbi F., Sarzi-Puttini P. et al. The clinical impact of anti-DFS70 antibodies in undifferentiated connective tissue disease: case reports and a review of the literature. Immunol Res. 2017; 65: 293–95.Infantino M., Meacci F., Grossi V., Manfredi M., Li Gobbi F., Sarzi-Puttini P. et al. The clinical impact of anti-DFS70 antibodies in undifferentiated connective tissue disease: case reports and a review of the literature. Immunol Res. 2017; 65: 293–95.Infantino M., Shovman O., Pérez D., Grossi V., Manfredi M., Benucci M. et al. A better defnition of the anti-DFS70 antibody screening by IIF methods. J Immunol Methods. 2018; 461: 110–16.Infantino M., Shovman O., Pérez D., Grossi V., Manfredi M., Benucci M. et al. A better defnition of the anti-DFS70 antibody screening by IIF methods. J Immunol Methods. 2018; 461: 110–16.Malyavantham K.S., Suresh L. Simultaneous Distinction of Monospecifc and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate. J Vis Exp 2018; (131): 56722.Malyavantham K.S., Suresh L. Simultaneous Distinction of Monospecifc and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate. J Vis Exp 2018; (131): 56722.Infantino M., Shovman O., Gilburd B., Manfredi M., Grossi V., Benucci M. et al. Improved accuracy in DFS pattern interpretation using a novel HEp-2 ELITE system. Clin Rheumatol. 2019; 38 (5): 1293–99.Infantino M., Shovman O., Gilburd B., Manfredi M., Grossi V., Benucci M. et al. Improved accuracy in DFS pattern interpretation using a novel HEp-2 ELITE system. Clin Rheumatol. 2019; 38 (5): 1293–99.Cheng C.F., Lan T.Y., Shih M.C., Li K.J. Monospecifc anti-DFS70 antibodies are moderately helpful in excluding ANA-associated rheumatic disease in patients presenting with a dense fne speckled pattern – A systematic review and metaanalysis of diagnostic test accuracy. Autoimmun Rev. 2020; 19 (10): 102637.Cheng C.F., Lan T.Y., Shih M.C., Li K.J. Monospecifc anti-DFS70 antibodies are moderately helpful in excluding ANA-associated rheumatic disease in patients presenting with a dense fne speckled pattern – A systematic review and metaanalysis of diagnostic test accuracy. Autoimmun Rev. 2020; 19 (10): 102637.Infantino M., Carbone T., Manfredi M., Grossi V., Benucci M., Casiano C.A., Bizzaro N. Dense fne speckled (DFS) immunofluorescence pattern and anti-DFS70 antibodies: Cleaning up the current concepts. Clin Chim Acta. 2020; 510: 157–59.Infantino M., Carbone T., Manfredi M., Grossi V., Benucci M., Casiano C.A., Bizzaro N. Dense fne speckled (DFS) immunofluorescence pattern and anti-DFS70 antibodies: Cleaning up the current concepts. Clin Chim Acta. 2020; 510: 157–59.

The authors declare that there are no conflicts of interest present.